BPC157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide whose sequence is a partial fragment of body protection compound, a protein discovered in and isolated from human gastric juice. Preclinical studies have examined its effects on angiogenesis, tendon fibroblast behavior, gastrointestinal mucosal healing and nitric oxide signaling, mostly in rodent and cell-culture models. Research Market supplies BPC-157 as a lyophilized research reagent, with purity and identity data for each lot reported on its certificate of analysis. It is sold strictly for laboratory research use.

Chemical structure and identification

• Molecular formula: C₆₂H₉₈N₁₆O₂₂
• Molecular weight: 1419.5 g/mol
• CAS number: 137525-51-0
• PubChem CID: 9941957
• Amino acid sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
• Form: Lyophilized powder
• Analytical methods: RP-HPLC for purity and mass spectrometry for identity, reported on the batch certificate of analysis

Research applications

• Wound healing and angiogenesis: Reviewed across rodent models of incisional and excisional skin wounds, deep burns, diabetic ulcers and fistulas, with attention to its effects on blood vessel formation during healing [1]
• Tendon fibroblasts: In explants and cultured fibroblasts from rat Achilles tendon, BPC-157 accelerated fibroblast outgrowth, improved cell survival under H₂O₂ stress and increased cell migration in a dose-dependent manner [2]
• Gastrointestinal mucosal integrity: Studied as a cytoprotective agent in preclinical models of gastrointestinal lesions, including the role of vascular recruitment in mucosal healing [3]
• VEGFR2 signaling: In endothelial cells and a rat hind-limb ischemia model, BPC-157 was associated with VEGFR2 up-regulation and activation of the VEGFR2–Akt–eNOS pathway [4]
• Nitric oxide system: Reviewed for its interaction with the nitric oxide system, including studies run alongside the NOS inhibitor L-NAME and the NO precursor L-arginine [5]

Reference citations

1. Seiwerth S. et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol, 12:627533. PMID 34267654 · DOI
2. Chang C.-H. et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol, 110(3):774–780. PMID 21030672 · DOI
3. Sikiric P. et al. (2018). Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des, 24(18):1990–2001. PMID 29879879 · DOI
4. Hsieh M.-J. et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl), 95(3):323–333. PMID 27847966 · DOI
5. Sikiric P. et al. (2014). Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des, 20(7):1126–1135. PMID 23755725 · DOI

Compound data from PubChem CID 9941957. Literature summaries describe published preclinical research and are not claims about this product’s effects in humans or animals.